晚期非小细胞肺癌中的新型免疫检查点抑制剂策略：迈向生物标志物驱动的疗法？ - Suppr

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

作者信息

Muntinghe-Wagenaar M Benthe, Hiltermann T Jeroen N

机构信息

Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

出版信息

Transl Lung Cancer Res. 2025 Feb 28;14(2):328-333. doi: 10.21037/tlcr-24-966. Epub 2025 Feb 24.

DOI:10.21037/tlcr-24-966

PMID:40114950

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11921232/

Abstract

摘要

相似文献

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?晚期非小细胞肺癌中的新型免疫检查点抑制剂策略：迈向生物标志物驱动的疗法？

Transl Lung Cancer Res. 2025 Feb 28;14(2):328-333. doi: 10.21037/tlcr-24-966. Epub 2025 Feb 24.

PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。

Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.

In Situ Detection of Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Interactions as a Functional Predictor for Response to Immune Checkpoint Inhibition in NSCLC.原位检测程序性细胞死亡蛋白1与程序性死亡配体1的相互作用作为非小细胞肺癌免疫检查点抑制反应的功能预测指标

J Thorac Oncol. 2025 May;20(5):625-640. doi: 10.1016/j.jtho.2024.12.026. Epub 2024 Dec 30.

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。

JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.

Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.2017年晚期非小细胞肺癌的新进展：免疫检查点抑制剂联合应用

J Thorac Dis. 2018 May;10(Suppl 13):S1534-S1546. doi: 10.21037/jtd.2018.04.99.

The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.PD-L1 表达在非小细胞肺癌中的意义：作为预测和预后标志物的锐利双刃剑。

Clin Lung Cancer. 2018 Mar;19(2):120-129. doi: 10.1016/j.cllc.2017.10.014. Epub 2017 Oct 28.

Cancer. 2021 Mar 1;127(5):777-786. doi: 10.1002/cncr.33270. Epub 2020 Oct 29.

Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.致癌驱动子亚型、程序性死亡受体-1 配体（PD-L1）评分和吸烟状态对驱动基因非小细胞肺癌患者 PD-1/PD-L1 抑制剂疗效的预测价值。

Cancer. 2019 Apr 1;125(7):1038-1049. doi: 10.1002/cncr.31871. Epub 2018 Dec 11.

Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.肿瘤表达及作为生物标志物在伴有预先存在的间质性肺病的晚期非小细胞肺癌患者中程序性死亡配体 1 的作用。

Med Oncol. 2019 Apr 27;36(6):49. doi: 10.1007/s12032-019-1274-0.

[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].[程序性死亡蛋白1/程序性死亡配体1抑制剂治疗转移性非小细胞肺癌患者的疗效及预后预测生物标志物的真实世界研究]

Zhonghua Zhong Liu Za Zhi. 2022 May 23;44(5):416-424. doi: 10.3760/cma.j.cn112152-20210709-00504.

本文引用的文献

Baseline Blood CD8 T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.基线血液CD8 T细胞激活能力可区分非小细胞肺癌患者中对免疫检查点抑制联合立体定向放射治疗有反应者与无反应者。

Cancers (Basel). 2024 Jul 19;16(14):2592. doi: 10.3390/cancers16142592.

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.生物标志物导向的靶向治疗联合度伐利尤单抗治疗晚期非小细胞肺癌：一项 2 期伞式试验。

Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13.

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.CheckMate 9LA 随机试验中，一线纳武利尤单抗联合伊匹单抗加化疗治疗转移性非小细胞肺癌的 4 年临床更新和治疗转换调整结局。

J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189.

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.将基因组生物标志物相结合，以指导非小细胞肺癌的免疫治疗。

Clin Cancer Res. 2024 Apr 1;30(7):1307-1318. doi: 10.1158/1078-0432.CCR-23-4027.

The cancer-immunity cycle: Indication, genotype, and immunotype.癌症免疫周期：指征、基因型和免疫型。

Immunity. 2023 Oct 10;56(10):2188-2205. doi: 10.1016/j.immuni.2023.09.011.

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC.ATM 突变与 NSCLC 中独特的共突变模式和治疗弱点相关。

Clin Cancer Res. 2023 Dec 1;29(23):4958-4972. doi: 10.1158/1078-0432.CCR-23-1122.

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.帕博利珠单抗联合培美曲塞和铂类化疗用于非鳞状非小细胞肺癌：III 期 KEYNOTE-189 研究的 5 年结果。

J Clin Oncol. 2023 Apr 10;41(11):1992-1998. doi: 10.1200/JCO.22.01989. Epub 2023 Feb 21.

Design and analysis of umbrella trials: Where do we stand?伞形试验的设计与分析：我们目前的进展如何？

Front Med (Lausanne). 2022 Oct 12;9:1037439. doi: 10.3389/fmed.2022.1037439. eCollection 2022.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.转移性非小细胞肺癌患者免疫治疗获得性耐药的临床定义。

Ann Oncol. 2021 Dec;32(12):1597-1607. doi: 10.1016/j.annonc.2021.08.2151. Epub 2021 Sep 3.

eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer.电子鼻分析用于非小细胞肺癌的早期免疫治疗反应监测。

Lung Cancer. 2021 Oct;160:36-43. doi: 10.1016/j.lungcan.2021.07.017. Epub 2021 Aug 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献